On July 13, 2026, Major Pharmaceuticals initiated a nationwide voluntary recall of multiple strengths and lot numbers of levothyroxine sodium tablets, a move that has sent ripples of concern through the millions of Americans who rely on the medication to manage thyroid disorders. The U.S. Food and Drug Administration (FDA) classified the recall as Class II, meaning the affected tablets—distributed widely across the United States—could cause temporary or medically reversible adverse health consequences, though the likelihood of serious harm is considered remote.
The recall was prompted by the discovery that certain lots of levothyroxine sodium tablets were subpotent, containing less active ingredient than required. According to the FDA, these subpotent tablets may not deliver the expected therapeutic effect, which is particularly troubling for patients with conditions such as hypothyroidism, goiter, Hashimoto's disease, and even thyroid cancer. The medication is a synthetic hormone designed to replace or supplement the body’s natural thyroid hormone, and even small deviations in potency can disrupt a patient’s carefully managed treatment plan.
The affected products—packaged in 10-count blister packs, either sold individually or in cartons containing ten blister packs—span twelve product lines and seven dosage strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 112 mcg, 125 mcg, and 150 mcg. Major Pharmaceuticals, headquartered in Indianapolis, was the primary distributor, with some lots further distributed by Cardinal Health. Patients are being urged to check the lot number and expiration date on both the outer carton and the individual blister packaging, as the recall is limited to specific lots and not every package of levothyroxine sodium tablets.
Levothyroxine is a cornerstone therapy for those living with thyroid disorders. As Dr. Abeer Hassoun, a pediatric endocrinologist at Columbia University Medical Center, explained to USA Today, “the bread and butter” of her patients’ treatment plans is levothyroxine. Many of her youngest patients, some just newborns, rely on the medication—crushed and mixed into formula or food—to ensure normal brain development and growth. “They will walk later,” Dr. Hassoun warned, referencing the consequences of inadequate dosing. “It can affect their growth and cognitive ability.” She added that children who are under-treated often display sluggishness and struggle academically, underscoring the importance of precise dosing.
For adult patients, the stakes are also high. Alexa Cimino, a 27-year-old thyroid cancer survivor, told ABC News that the recall was “genuinely horrifying.” She described her daily reliance on levothyroxine as a “daily act of trust,” adding, “The thought that a dose might not be as strong as it's supposed to be is genuinely horrifying. You build your life around believing that medication is protecting you, and a recall like this shakes that trust in a way that's hard to describe.”
Patients who believe they may have received affected tablets are strongly encouraged to consult their doctor or pharmacist before making any changes to their medication regimen. The FDA and multiple health experts stress that patients should not discontinue their medication unless specifically directed by a healthcare provider. Abruptly stopping levothyroxine can cause symptoms of hypothyroidism to return or worsen, including fatigue, weight gain, cold sensitivity, and cognitive difficulties. The recall’s Class II classification means that while the risk of lasting harm is low, temporary health effects are possible if patients are under-treated due to subpotent medication.
According to the recall notices reviewed by Reuters, the impacted lots include tablets with expiration dates ranging from July 2026 through January 2027. The detailed list of affected dosages and lot numbers was made available by the FDA, but no press release was issued by Major Pharmaceuticals. Instead, notification to consignees and the public was made by letter, leaving some patients and healthcare providers scrambling for information.
Healthcare providers and pharmacies that have distributed affected lots have been instructed to follow standard recall procedures, which include quarantining any remaining inventory to prevent further dispensing. For patients, the most practical step is to check the packaging—both the outer carton and the individual blister packs—for the lot number and expiration date. If the medication matches an affected lot, patients should immediately contact their healthcare provider for guidance on next steps.
Dr. Hassoun emphasized that endocrinologists routinely monitor their patients’ thyroid hormone levels and adjust dosages as needed, regardless of the label. “Some of them might need to be given more, and some of them might need less ... it's not very concerning as long as I follow the patients,” she told ABC News. However, she acknowledged that the recall could pose challenges for patients whose insurance policies do not cover alternative, often more expensive, brand-name medications like Synthroid. “It's cheaper than the brand-name Synthroid,” Dr. Hassoun said of the recalled levothyroxine sodium tablets. “If the insurance doesn't cover it, it will be more difficult. I have to say it will be troublesome to manage.”
The recall covers a wide range of dosages, including 25 mcg, 50 mcg, 75 mcg, 88 mcg, 112 mcg, 125 mcg, and 150 mcg tablets. Each of these strengths is vital for tailoring treatment to individual patient needs, from infants with congenital hypothyroidism to adults managing post-cancer thyroid replacement. The fact that the recall includes both 10 x 10 unit dose blisters and 10 x 1 unit dose blisters means patients and providers alike must be vigilant in checking their medication against the recall list.
Levothyroxine sodium’s role in managing thyroid conditions cannot be overstated. For those with hypothyroidism, the synthetic hormone is often a lifelong necessity. Even minor lapses in potency can lead to symptoms returning or worsening—symptoms that can affect every aspect of daily life, from energy levels to cognitive function. According to MedPage Today, subpotent tablets may leave patients under-treated, causing hypothyroid symptoms such as fatigue, weight gain, cold sensitivity, and cognitive difficulties to persist or worsen.
The FDA’s Class II recall designation is meant to reflect the relative risk associated with the subpotent medication. Class I recalls are reserved for products that could cause serious injury or death, while Class III recalls involve products unlikely to cause any adverse health consequences. In this case, the FDA determined that the probability of serious harm is remote, but the potential for temporary or reversible effects remains—a distinction that matters deeply to those who depend on precise dosing for their well-being.
As the recall continues, patients, pharmacists, and healthcare providers are working together to ensure that those affected can access safe and effective alternatives. The episode serves as a stark reminder of the trust patients place in the medications they take and the importance of vigilance throughout the pharmaceutical supply chain. For now, the best advice remains: check your lot numbers, consult your healthcare provider, and do not stop your medication unless instructed to do so. In a world where a tiny tablet can make all the difference, a little caution goes a long way.